references
24. Safarinejad, M. R., 2005. Urtica Dioica for Treatment of Benign Prostatic Hyperplasia: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study. J Herb Pharmacother 5( 4): 1 – 11. 25. Sarma, V., and J. Kellog Parsons. 2009. Diabetes and Benign Prostatic Hyperplasia: Emerging Clinical Connections. Curr Urol Rep 10( 4): 267 – 75. 26. Schenk, J. M., et al. 2011 Jun 15. Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Am J Epidemiol 173( 12): 1419 – 28. 27. Sea, J., et al. 2009 Dec. Review of Exercise and the Risk of Benign Prostatic Hyperplasia. Phys Sportsmed 37( 4): 75 – 83. 28. Vogel, S. a. 2009 Nov. the Politics of Plastics: The Making and Unmaking of Bisphenol a“ Safety.” Am J Public Health 99 Suppl 3: S559 – 66. 29. Wang, C., et al. 2010 May 21. Tai Chi on Psychological Well-Being: Systematic Review and Meta-Analysis. Bmc Complement Altern Med 10:23. 30. Wilt, T. J., et al. 1999 Jun. a Beta-Sitosterol for the Treatment of Benign Prostatic Hyperplasia: Systematic Review. Bju Int 83( 9): 976 – 83. 31. Yan, M., et al. 2010 Aug. Differential Response to Zinc-Induced Apoptosis in Benign Prostate Hyperplasia and Prostate Cancer Cells. J Nutr Biochem 21( 8): 687 – 94. 32. Yang, Y. J., et al. 1999 Aug. Comparison of Fatty Acid Profiles In the Serum of Patients With Prostate Cancer and Benign Prostatic Hyperplasia. Clin Biochem 32( 6): 405 – 9. 33. Yang. a., et al. 2009 Mar. Effects of Soy Bean Isoflavone on Inhibition of Benign Prostatic Hyperplasia and the Expressions of No and Nos of Rats. Wei Sheng Yan Jiu 38( 2): 172 – 74. 34. Yokoyama, T., et al. 2012 Aug. Intraprostatic Botulinum Neurotoxin Type a Injection for Benign Prostatic Hyperplasia: Preliminary Results With a Newly Purified Neurotoxin. Acta Med Okayama; 66( 4): 291 – 97. 35. Zeligs, M. a. the Cruciferous Choice: Diindolylmethane or I3c? Access at Http:// Www. Dimfaq. Com / Site / Cruchoice. Htm
72